补髓生血颗粒对慢性髓劳病患者T淋巴细胞亚群、IL-17、IL-17mRNA和RORγtmRNA影响的研究

Effect of Busui Shengxue Granule on T-lymphocyte Subsets,Interleukin-17,Interleukin-17 mRNA and RORγtmRNA in Chronic Suilao Disease Patients

目的:通过观察补髓生血颗粒对慢性髓劳病患者治疗前后外周血T淋巴细胞亚群、IL-17、IL-17mRNA和RORγtmRNA表达水平的变化,探讨补髓生血颗粒治疗慢性髓劳病患者免疫失衡的作用机制和疗效机理。方法:按照诊断标准收治30例慢性髓劳病患者,应用FCM检测慢性髓劳病患者治疗前后T淋巴细胞亚群(CD_4^+、CD_8^+、CD_4^+/CD_8^+)表达比例的变化,ELISA法检测慢性髓劳病患者治疗前后IL-17表达水平的变化,RT-PCR法检测慢性髓劳病患者治疗前后IL-17mRNA和RORγtmRNA表达水平的变化。结果:疗前试验组慢性髓劳病患者CD_4^+细胞比例、CD_4+/CD_8^+比值降低,CD_8^+细胞比例增高,与正常对照组相比均有显著性差异(P<0.05)。疗后试验组CD_4^+细胞比例、CD_4^+/CD_8^+比值升高,CD_8^+细胞比例下降,与疗前相比均有显著性差异(P<0.05);疗前试验组慢性髓劳病患者IL-17、IL-17mRNA和RORγtmRNA的表达水平均高于正常组,与正常对照组相比均有显著性差异(P<0.05),疗后较疗前下降,相比均具有显著性差异(P<0.05)。结论:1补髓生血颗粒通过调整异常表达的T淋巴细胞数量和比值,进而抑制亢进的细胞免疫状态,以促进骨髓造血功能的恢复;2补髓生血颗粒通过下调IL-17、IL-17mRNA和RORγtmRNA的表达水平,以恢复因免疫损伤而导致的骨髓造血功能障碍,进而促进造血干/祖细胞的增殖和分化;3补髓生血颗粒具有调整慢性髓劳病患者免疫失衡的作用,这可能是补髓生血颗粒治疗慢性髓劳病的作用机制之一。

Objective： To observe the effect of Busui Shengxue Granule on T-lymphocyte subsets,interleukin-17,interleukin-17 mRNA and RORγtmRNA in patients with chronic Suilao disease. Elaborate the mechanism of immuneimbalance and provide the theoretical basiswith Busui Shengxue Granule in chronic Suilao disease. Methods： A total of 30 cases of chronic Suilao disease patients were treated according to diagnostic criteria. The expressions of T-lymphocyte subsets（ CD4^＋、CD8^＋、CD4^＋/ CD8^＋）were detected by flow cytometry before and after treatment. We compared peripheral blood levels of interleukin-17 by ELISA before and after treatment and the interleukin-17 mRNA andRORγtmRNA levels in peripheral blood detected with RT-PCR. Results： 1The expressions of CD4^＋ and CD4^＋/ CD8^＋ were lower and CD8^＋ higher in experiment group before treatment and the differences were significant compared with those of the normal group（ P〈0.05）. The expressions of CD4^＋ and CD4^＋/ CD8^＋ were higher and CD8^＋ lower in experiment group after treatment and the differences were significant（ P〈0.05）. 2The levels of interleukin-17,interleukin-17 mRNA and RORγtmRNAin experiment group were higher compared with those of the normal group before treatment and the differences were significant compared with those of the normal group（ P〈0.05）. The level of them were lower after treatment and there were significant differences（ P〈0. 05）. Conclusion： 1Busui Shengxue Granule might restrain abnormal cellular immunity by regulating abnormal expressions of T-lymphocyte subsets to promote hemopoietic function of marrow. 2Busui Shengxue Granule could reduce the levels of interleukin-17,interleukin-17 mRNA and RORγtmRNA to recover hemopoietic function of bone marrow due to immune injury,increase proliferationand differentiation of hematopoietic stem / progenitor cells. 3Busui Shengxue Granule plays a role in regulating immune imbalance of chronic Suilao disease,which might be the mechanism of Busui Shengxue Granule to treat chronic Suilao disease.